McKesson (MCK) Upgraded to Buy: Here's Why
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy McKesson (MCK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See McKesson (MCK) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
Drug distributor McKesson to buy controlling stake in Core Ventures for about $2.5 bln
Drug distributor McKesson said on Monday it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core Ventures, for $2.49 billion in cash.
McKesson to acquire controlling stake in Core Ventures for $2.49 billion in cash
McKesson Corp. MCK, -1.56% said Monday it has agreed to acquire a controlling stake in Community Oncology Revitalization Enterprise Ventures, LLC , or Core Ventures, a physician-owned community oncology practice to about $2.49 billion in cash. Once the deal closes, Core Ventures will become part of McKesson's oncology network.
McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?
McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
McKesson Revenue Hurt by Supply and Demand Issues for Weight-Loss Drugs
McKesson (MCK) shares tumbled Thursday, a day after the healthcare services provider warned that limited supply of GLP-1 weight-loss drugs is hurting sales.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Thursday.
McKesson (MCK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
